Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Warts 2

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × 2-Propanol × Clear all
NCT03691831 2020-10-27

A Study of A-101 Topical Solution for the Treatment of Common Warts

Aclaris Therapeutics, Inc.

Phase 3 Completed
502 enrolled 22 charts

Warts

NCT03687372 2020-10-05

Study of A-101 Topical Solution for the Treatment of Common Warts

Aclaris Therapeutics, Inc.

Phase 3 Completed
503 enrolled 22 charts

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡